Low-dose aspirin cuts dementia risk 70% in specific genotypes

For years, trials testing low-dose aspirin for cognitive decline delivered a flat zero. Large cohorts like the ASPREE trial (n=19,114) tracked adults taking 100 mg daily and found no broad protective effect against dementia, while recording the predictable uptick in gastrointestinal bleeding risks. That flat result convinced most clinicians to shelf aspirin as a general brain preservation tool. New stratified analyses challenge that broad dismissal.

When researchers separated participants by distinct genetic inflammatory markers, the pooled data told a different story. Older adults carrying specific risk variants who took low-dose aspirin showed a 70% lower relative risk of developing dementia compared to non-users with the same profile. For those without the variant, the drug offered no cognitive advantage while retaining its baseline bleeding liability.

The mechanism centers on vascular inflammation and microglial overactivation. In brains predisposed to runaway neuroinflammation, low-dose acetylsalicylic acid suppresses cyclooxygenase pathways before structural damage accumulates. In brains where dementia pathways are driven primarily by amyloid clearance defects or tau tangles rather than this specific inflammatory cascade, the molecule does nothing useful.

Before you add an over-the-counter pill to your morning routine based on an anti-aging headline, inspect your raw data. If you have run a personal genetic panel, look for your specific neuroinflammatory markers with a physician rather than treating an off-the-shelf blood thinner as a catch-all prophylactic.